Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Receives $7.67 Average PT from Brokerages

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.6667.

Several research firms have issued reports on PLYX. Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Wednesday, July 1st. Raymond James Financial initiated coverage on Polaryx Therapeutics in a research note on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target on the stock. HC Wainwright initiated coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 target price for the company. Wall Street Zen lowered shares of Polaryx Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th.

Polaryx Therapeutics Stock Performance

Shares of PLYX stock opened at $2.08 on Monday. Polaryx Therapeutics has a 1 year low of $1.85 and a 1 year high of $48.91. The business’s fifty day moving average is $2.21 and its 200-day moving average is $3.46. The stock has a market cap of $103.68 million and a PE ratio of -26.00.

Polaryx Therapeutics (NASDAQ:PLYX) last released its earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Equities research analysts predict that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.